Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02998476 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
A Phase 2 study of Lymphoma, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT02998476: Completed Phase 2 study of Lymphoma, sponsored by Incyte Corporation.
NCT02998476 is a Phase 2 study of Lymphoma that has completed, run by Incyte Corporation. The registered enrollment target is 60 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02998476, a Phase 2 study of Lymphoma, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Primary Outcome
Defined as the percentage of subjects with a complete or partial response as defined by Lugano Classification criteria for lymphomas (Cheson et al 2014) as determined by IRC.
Conditions Studied
Interventions
- DRUG Parsaclisib
Study Locations (20)
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Arizona Oncology Associates, PC - HAL - Tempe
California
- Sutter Gould Medical Foundation - Modesto
- Sharp Memorial Hospital - San Diego
Florida
- Advanced Pharma CR, LLC - Miami
- Asclepes Research Centers - Weeki Wachee
Indiana
- Indiana BMT - Beech Grove
- Parkview Research Center - Fort Wayne
Michigan
- Karmanos Cancer Institute - Detroit
- St. John Hospital and Medical Center - Detroit
New Jersey
- Summit Medical Group - Morristown
- Rutgers Cancer Institute of New Jersey - New Brunswick
Alabama
- University of Alabama at Birmingham - Birmingham
Illinois
- Advocate Medical Group Niles Milwaukee Ave - Niles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-03-02 |
| Est. Completion | 2021-02-05 |
| Phase | Phase 2 |
What the finished NCT02998476 record still lists
NCT02998476 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Parsaclisib is the first listed.
NCT02998476 names 20 study sites across 14 states, led by Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02998476 about?
NCT02998476 is a clinical study titled "A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)". The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.
What is the current status of trial NCT02998476?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2017-03-02. Estimated completion is 2021-02-05.
What conditions does trial NCT02998476 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT02998476?
The interventions under investigation include: Parsaclisib (DRUG).
Who is sponsoring clinical trial NCT02998476?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02998476 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02998476's enrollment target sits among peer trials
60 129th of 299 higher than 163 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI